Bio-Path Holdings, Inc. (BPTH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bio-Path Holdings, Inc. (BPTH) trades at $0.05 with AI Score 44/100 (Grade C). Bio-Path Holdings, Inc. is a U. S. Market cap: $429,739, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for BPTH: BPTH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BPTH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BPTH: the 1 perspectives are evenly split.
How is this calculated? →Bio-Path Holdings, Inc. (BPTH) Healthcare & Pipeline Overview
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company developing RNAi nanoparticle drugs for oncology. Leveraging its DNAbilize platform, the company advances clinical and preclinical programs, including lead candidate prexigebersen in Phase II trials for AML and MDS, aiming to address significant unmet medical needs in cancer treatment.
What Is the Investment Thesis for BPTH?
Bio-Path Holdings, Inc. presents a research focus on its proprietary DNAbilize platform, which is designed to deliver RNAi nanoparticle drugs for oncology applications. The company's lead candidate, prexigebersen, is in Phase II clinical trials for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), representing a significant value driver as it progresses through regulatory pathways. The broad pipeline, including Liposomal Bcl-2 for lymphoma/CLL and Liposomal STAT3 for pancreatic/NSCLC/AML, indicates potential for multiple future revenue streams upon successful development and commercialization. The P-ethoxy modified DNA backbone technology aims to offer a differentiated approach to drug stability and delivery, which could provide a competitive advantage in the challenging oncology market. However, the investment thesis is subject to the inherent risks of biotechnology, including the high failure rate of clinical trials, the extensive capital requirements for drug development, and the uncertainties of regulatory approvals. Success hinges on positive clinical data, successful navigation of FDA processes, and securing future funding.
Based on FMP financials and quantitative analysis
BPTH Key Highlights
- Market Capitalization: $0.00B, reflecting the company's early-stage development and valuation.
- Free Cash Flow: $0.00B, typical for a clinical-stage biotechnology company focused on R&D expenditures.
- Beta: -0.41, indicating a low correlation with broader market movements, potentially due to company-specific clinical trial catalysts.
- Lead drug candidate prexigebersen is in Phase II clinical trials for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), representing a key advancement in its pipeline.
- Proprietary DNAbilize platform utilizes a P-ethoxy modified deoxyribonucleic acid (DNA) backbone, engineered to shield DNA from premature degradation and enhance drug delivery.
Who Are BPTH's Competitors?
BPTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| ABVX Abivax S.A. | $143.99 | -0.46% | 10B | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| MIRM Mirum Pharmaceuticals, Inc. | $121.91 | -2.93% | $6.12B | 68 |
| BCYC Bicycle Therapeutics plc | $4.37 | +0.54% | $303.50M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BPTH's Key Strengths?
- Proprietary DNAbilize platform offers a differentiated approach to RNAi drug delivery with enhanced stability.
- Lead drug candidate, prexigebersen, is in Phase II clinical trials, indicating significant progress in development.
- Diverse oncology pipeline targeting multiple challenging cancer indications (AML, MDS, lymphoma, CLL, pancreatic, NSCLC).
- Focus on unmet medical needs in oncology, a high-value therapeutic area.
What Are BPTH's Weaknesses?
- Small company size with 10 employees, potentially limiting resources for extensive parallel development.
- Absence of commercialized products, leading to reliance on R&D funding and capital raises.
- High burn rate typical of clinical-stage biotechnology companies without current revenue streams.
- Limited financial data available, with Market Cap and FCF both reported as $0.00B.
What Could Drive BPTH Stock Higher?
- Announcement of clinical data from the ongoing Phase II trials for prexigebersen in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Positive data could significantly de-risk the program and attract further investment or partnerships.
- Initiation of new clinical trials or advancement of existing preclinical candidates (e.g., Liposomal STAT3) into human trials. This would expand the pipeline and demonstrate continued progress.
- Potential for strategic partnerships or licensing agreements for the DNAbilize platform or specific drug candidates, which could provide non-dilutive funding and validation.
- Regulatory updates or guidance from health authorities (e.g., FDA) regarding the development pathway for prexigebersen or other pipeline assets.
What Are the Key Risks for BPTH?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failure or unexpected adverse events for prexigebersen or other drug candidates, which could halt development and significantly impact company valuation.
- Significant capital requirements for continued research and development, clinical trials, and regulatory processes, potentially leading to future equity dilution.
- Regulatory hurdles and delays in obtaining necessary approvals from health authorities, which can extend timelines and increase costs.
- Intense competition within the oncology and biotechnology sectors, with larger companies possessing greater resources for R&D and commercialization.
- Dependence on the success of a limited number of drug candidates, particularly prexigebersen, making the company highly susceptible to individual program outcomes.
What Are the Growth Opportunities for BPTH?
- Growth opportunity 1: Successful advancement and commercialization of prexigebersen for AML and MDS. Prexigebersen is the company's lead drug candidate, currently in Phase II clinical trials. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) represent significant unmet medical needs with substantial market potential. Positive clinical trial results and subsequent regulatory approval could unlock a new therapeutic option for patients and establish a primary revenue stream for Bio-Path. The market for AML treatments alone is projected to reach several billion dollars globally, indicating a substantial opportunity for a novel, effective therapy.
- Growth opportunity 2: Development and approval of Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL). Bcl-2 inhibitors are a class of drugs targeting a protein often overexpressed in various lymphomas and leukemias. Bio-Path's Liposomal Bcl-2 aims to provide a novel approach within this therapeutic area, potentially offering improved efficacy or safety profiles. The global market for lymphoma and CLL treatments is robust and growing, driven by an aging population and advancements in treatment paradigms. Successful development could position this candidate as a valuable asset in a competitive but large market.
- Growth opportunity 3: Progression of Liposomal STAT3 from preclinical to clinical stages for pancreatic cancer, non-small cell lung cancer (NSCLC), and AML. STAT3 is a transcription factor implicated in various cancers, and targeting it represents a promising strategy. Pancreatic cancer and NSCLC are particularly aggressive and difficult-to-treat cancers with high unmet needs, commanding significant research and development efforts. Advancing Liposomal STAT3 into human trials would validate the preclinical findings and open up substantial market opportunities in these challenging indications, potentially attracting partnerships or further investment.
- Growth opportunity 4: Expansion of prexigebersen-A into various solid tumors. While prexigebersen is focused on hematologic malignancies, prexigebersen-A is being developed for solid tumors, which represent a much larger and more diverse market segment than liquid tumors. The ability to apply the DNAbilize platform to a broad range of solid tumor types could significantly expand Bio-Path's addressable market and therapeutic reach. Success in even a few solid tumor indications could lead to substantial market penetration and revenue generation, diversifying the company's pipeline beyond its initial focus.
- Growth opportunity 5: Strategic partnerships and licensing agreements leveraging the DNAbilize platform. The proprietary DNAbilize platform, with its P-ethoxy modified DNA backbone designed for enhanced stability and delivery, represents a foundational technology. Beyond its internal pipeline, Bio-Path could explore collaborations with larger pharmaceutical companies interested in applying this platform to their own drug candidates or therapeutic areas. Such partnerships could provide non-dilutive funding, accelerate development timelines, and validate the platform's broader utility, opening new revenue streams through licensing fees, milestone payments, and royalties.
What Opportunities Does BPTH Have?
- Successful clinical trial outcomes could lead to accelerated regulatory pathways and market entry.
- Potential for strategic partnerships or licensing agreements to fund development and expand market reach.
- Expansion of the DNAbilize platform to new indications or therapeutic areas beyond current oncology focus.
- Addressing significant unmet medical needs in challenging cancers with potentially superior therapeutic options.
What Threats Does BPTH Face?
- High risk of clinical trial failure, which could lead to significant delays or termination of drug candidates.
- Intense competition from larger pharmaceutical companies with greater resources in the oncology market.
- Stringent and lengthy regulatory approval processes, which can delay market entry.
- Need for substantial ongoing funding to support research, development, and clinical trials, with potential for dilution.
What Are BPTH's Competitive Advantages?
- Proprietary DNAbilize platform: A unique drug delivery and antisense technology utilizing a P-ethoxy modified DNA backbone, designed to enhance drug stability and efficacy.
- Advanced clinical pipeline: Lead drug candidate prexigebersen is in Phase II trials, representing a significant hurdle overcome in drug development and a potential first-in-class or best-in-class therapy.
- Targeted oncology focus: Specialization in RNAi nanoparticle drugs for specific cancer indications allows for focused expertise and potential for highly effective treatments.
- Intellectual property: Patents protecting the DNAbilize platform and specific drug candidates provide a barrier to entry for competitors.
- Early-mover advantage in specific RNAi applications: Developing novel approaches to target challenging cancer pathways like Bcl-2 and STAT3 with a unique delivery system.
What Does BPTH Do?
Bio-Path Holdings, Inc., founded in 2007 and headquartered in Bellaire, Texas, is a U.S.-based pharmaceutical company dedicated to the development of innovative RNAi nanoparticle drugs specifically for oncology. The company's strategic focus lies in addressing various cancers through its proprietary DNAbilize platform, an advanced drug delivery and antisense technology. This platform is distinguished by its use of a P-ethoxy modified deoxyribonucleic acid (DNA) backbone, a critical engineering feature designed to protect the DNA from premature degradation within the body, thereby enhancing drug stability and efficacy. Bio-Path's product development pipeline spans both clinical and preclinical stages, demonstrating a comprehensive approach to therapeutic innovation. The flagship drug candidate, prexigebersen, represents a significant asset, currently progressing through Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), two challenging hematologic malignancies. Beyond prexigebersen, the company is actively advancing Liposomal Bcl-2, targeting refractory/relapsed lymphoma and chronic lymphocytic leukemia, and Liposomal STAT3, which is in preclinical development for indications such as pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development with potential applications across various solid tumors, showcasing the versatility and broad applicability of Bio-Path's core technology. With a lean team of 10 employees, Bio-Path Holdings, Inc. maintains a specialized focus on its oncology pipeline, aiming to bring novel treatments to market.
What Products and Services Does BPTH Offer?
- Develops RNAi nanoparticle drugs for oncology.
- Utilizes the proprietary DNAbilize platform for drug delivery and antisense technology.
- Engineers drugs with a P-ethoxy modified DNA backbone to prevent premature degradation.
- Advances prexigebersen, a lead drug candidate, through Phase II clinical trials for AML and MDS.
- Develops Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia.
- Conducts preclinical development of Liposomal STAT3 for pancreatic cancer, non-small cell lung cancer, and AML.
- Explores prexigebersen-A for various solid tumors.
- Focuses on addressing unmet medical needs in cancer treatment.
How Does BPTH Make Money?
- Primarily focused on research and development of novel oncology therapeutics.
- Aims to generate revenue through the successful clinical development, regulatory approval, and commercialization of its drug candidates.
- Potential future revenue streams include direct sales of approved drugs, licensing agreements, and strategic partnerships with larger pharmaceutical companies.
- Currently operates as a clinical-stage biotechnology company, with significant investment in R&D and clinical trials.
- Relies on capital raises and grants to fund ongoing drug development and operational expenses.
What Industry Does BPTH Operate In?
Bio-Path Holdings, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on oncology. The global oncology drug market is characterized by continuous innovation, driven by increasing cancer incidence and demand for more effective and targeted therapies. RNAi nanoparticle drugs represent a cutting-edge segment within this market, offering potential for precision medicine by silencing specific genes involved in cancer progression. Bio-Path's DNAbilize platform positions it within the advanced drug delivery and antisense technology space, seeking to overcome challenges associated with traditional RNAi delivery. The company competes with numerous pharmaceutical and biotechnology firms developing novel cancer treatments, including those focused on gene therapies, immunotherapies, and small molecule inhibitors. Its success will depend on demonstrating superior efficacy, safety, and a differentiated mechanism of action compared to existing and emerging therapies in its targeted indications.
Who Are BPTH's Key Customers?
- Oncology patients suffering from acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), lymphoma, and chronic lymphocytic leukemia (CLL).
- Healthcare providers, including oncologists and hematologists, seeking advanced treatment options for their cancer patients.
- Hospitals and cancer treatment centers that administer specialized oncology drugs.
- Potentially, pharmaceutical companies seeking to license or partner on the DNAbilize platform or specific drug candidates.
Company Profile
Bio-Path Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bellaire, US. The company is led by CEO Vikram Paul Grover. BPTH has traded publicly since 2008.
F-Score 1/9Financial Health
Bio-Path Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 76%Key Financial Metrics
Return on equity for Bio-Path Holdings, Inc. stands at 76.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.07 means current liabilities exceed short-term assets, a liquidity point worth watching.
BPTH Valuation & Market Position
With a 430K market cap, Bio-Path Holdings, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BPTH's quantitative score of 44/100 is below the peer average of 76/100.
FY2026 estForward Outlook
Wall Street analysts project Bio-Path Holdings, Inc. revenue of about $40.1M for fiscal 2026, with EPS near $-1.42.
BPTH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary DNAbilize platform offers a differentiated approach to RNAi drug delivery with enhanced stability.
- Lead drug candidate, prexigebersen, is in Phase II clinical trials, indicating significant progress in development.
- Diverse oncology pipeline targeting multiple challenging cancer indications (AML, MDS, lymphoma, CLL, pancreatic, NSCLC).
- Focus on unmet medical needs in oncology, a high-value therapeutic area.
Bear Case
- Small company size with 10 employees, potentially limiting resources for extensive parallel development.
- Absence of commercialized products, leading to reliance on R&D funding and capital raises.
- High burn rate typical of clinical-stage biotechnology companies without current revenue streams.
- Limited financial data available, with Market Cap and FCF both reported as $0.00B.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
BPTH Latest News
-
Bio-Path Holdings Q1 EPS $(0.03) Up From $(0.40) YoY
benzinga · May 20, 2026
-
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
benzinga · Jun 3, 2024
BPTH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BPTH.
Price Targets
Wall Street price target analysis for BPTH.
BPTH MoonshotScore
What does this score mean?
The MoonshotScore rates BPTH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Vikram Paul Grover
CEO
Vikram Paul Grover leads Bio-Path Holdings, Inc. as its CEO, overseeing the company's strategic direction and operational execution. With a focus on developing RNAi nanoparticle drugs for oncology, Mr. Grover is responsible for guiding the advancement of the proprietary DNAbilize platform and its pipeline candidates. His leadership is critical in navigating the complex landscape of pharmaceutical research and development, particularly in the specialized field of cancer therapeutics. The company, under his management, operates with a team of 10 employees, emphasizing a lean and focused approach to drug development.
Track Record: Under Vikram Paul Grover's leadership, Bio-Path Holdings, Inc. has progressed its lead drug candidate, prexigebersen, into Phase II clinical trials for acute myeloid leukemia and myelodysplastic syndrome. This advancement represents a significant milestone in the company's development pipeline. His strategic oversight has been instrumental in maintaining the company's focus on its RNAi nanoparticle drug platform and its application in oncology, guiding the team through critical preclinical and clinical development stages.
BPTH OTC Market Information
Bio-Path Holdings, Inc. trades on the 'OTC Other' tier of the OTC Markets. This tier is typically for companies that do not meet the disclosure or financial standards of OTCQX or OTCQB, or choose not to provide information to OTC Markets Group. Companies on the 'OTC Other' tier may not have current or publicly available information, making it challenging for investors to conduct thorough due diligence. It often includes distressed companies, those with limited public interest, or those that have not filed with the SEC or other regulatory bodies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and disclosure, making comprehensive due diligence challenging for investors.
- Lower liquidity and wider bid-ask spreads, potentially leading to difficulty in executing trades at fair prices.
- Increased volatility due to thin trading and speculative interest, rather than fundamental analysis.
- Higher susceptibility to fraud and manipulation due to less stringent reporting requirements and oversight.
- Difficulty in obtaining financing or attracting institutional investors due to perceived risks and lack of transparency.
- Verify the company's current operational status and any recent public announcements or press releases.
- Scrutinize any available financial statements, even if unaudited, for cash burn, debt levels, and R&D expenditures.
- Research the management team's background, experience, and any past regulatory issues.
- Assess the clinical trial progress and scientific validity of their drug candidates through independent sources.
- Examine any intellectual property filings or patents to understand the strength of their competitive position.
- Evaluate the company's funding history and future capital requirements, considering potential dilution.
- Monitor trading volume and bid-ask spreads to gauge liquidity before considering any investment.
- Active clinical trial programs (Phase II for prexigebersen) indicate ongoing scientific development and regulatory engagement.
- Specific focus on a proprietary technology (DNAbilize platform) suggests a defined business strategy.
- Identified headquarters in Bellaire, US, and a stated number of employees (10) provide a tangible presence.
- Publicly named CEO (Vikram Paul Grover) provides a clear point of accountability for leadership.
BPTH Healthcare Stock FAQ
What does Bio-Path Holdings, Inc. do?
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company specializing in the development of RNAi nanoparticle drugs for oncology. Its core innovation is the DNAbilize platform, an advanced drug delivery and antisense technology that uses a P-ethoxy modified DNA backbone to protect therapeutic DNA from degradation. The company's pipeline includes prexigebersen, currently in Phase II trials for AML and MDS, Liposomal Bcl-2 for lymphoma and CLL, Liposomal STAT3 in preclinical development for pancreatic cancer, NSCLC, and AML, and prexigebersen-A for solid tumors. The company's mission is to bring novel cancer treatments to market by leveraging its proprietary technology.
How does Bio-Path Holdings, Inc. navigate regulatory approval processes?
Bio-Path Holdings, Inc. navigates regulatory approval processes by systematically progressing its drug candidates through preclinical studies and multiple phases of clinical trials, adhering to stringent regulatory guidelines. Its lead candidate, prexigebersen, is currently in Phase II clinical trials, a critical stage where efficacy and safety are further evaluated in a larger patient population. Successful completion of Phase II, followed by Phase III trials, is essential for demonstrating the drug's clinical benefit. The company must compile comprehensive data packages for submission to regulatory bodies like the FDA, which then review the data for approval. This process involves continuous interaction with regulators, adherence to Good Clinical Practice (GCP), and meticulous documentation to ensure compliance and facilitate potential market authorization.
What are the main risks for BPTH?
The primary risks for Bio-Path Holdings, Inc. are inherent to the biotechnology sector, particularly the high probability of clinical trial failure. Any negative outcomes in the ongoing Phase II trials for prexigebersen, or future trials for other candidates, could severely impact the company's prospects. Significant capital is required to fund research, development, and clinical trials, posing an ongoing risk of dilution through future equity raises. Regulatory hurdles, including delays or outright rejection of drug candidates by health authorities, also represent substantial threats. Furthermore, the company faces intense competition from larger pharmaceutical firms with greater financial and research resources, and its reliance on a limited pipeline means that the success or failure of a few key programs will largely determine its future.
What revenue streams does Bio-Path Holdings, Inc. have in healthcare?
As a clinical-stage pharmaceutical company, Bio-Path Holdings, Inc. currently does not have commercialized products generating revenue from sales. Its primary focus is on research and development. In the future, if its drug candidates successfully complete clinical trials and receive regulatory approval, the company anticipates generating revenue through the direct sale of its approved oncology drugs. Additionally, Bio-Path may pursue strategic partnerships or licensing agreements with larger pharmaceutical companies. These collaborations could provide revenue through upfront payments, milestone payments tied to development progress, and royalties on future sales, leveraging its proprietary DNAbilize platform and pipeline assets.
What is Bio-Path Holdings, Inc.'s strategy for pipeline development?
Bio-Path Holdings, Inc.'s pipeline development strategy is centered on its proprietary DNAbilize platform, which is designed to deliver RNAi nanoparticle drugs for oncology. The company aims to leverage this platform to create a diversified portfolio of cancer therapeutics. The strategy involves advancing lead candidates like prexigebersen through rigorous clinical trials (currently Phase II) for specific indications such as AML and MDS. Concurrently, it pursues preclinical development for other promising assets like Liposomal Bcl-2 and Liposomal STAT3, targeting additional hematologic and solid tumors. This multi-pronged approach seeks to maximize the potential of its core technology across various high-unmet-need cancer types, while managing the inherent risks of drug development by having multiple programs in different stages.
What are the key factors to evaluate for BPTH?
Bio-Path Holdings, Inc. (BPTH) holds an AI score of 44/100 (low). Not financial advice.
How frequently does BPTH data refresh on this page?
BPTH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BPTH's recent stock price performance?
Bio-Path Holdings, Inc. (BPTH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary DNAbilize platform offers a differentiated approach to RNAi drug delivery with enhanced stability. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial metrics (Market Cap, FCF) are stated as $0.00B as per source data, which is unusual and may indicate very low or negligible values.
- CEO's specific background and track record details beyond managing employees and drug progression are not provided in the source data, leading to generalized statements.
- Competitor information was not provided in the source data, resulting in an empty array.
- Disclosure status for OTC is 'Unknown' as per source data, which is a significant factor for OTC analysis.